Clinical Study IV was designed to evaluate the targeted benefits of VERISOL® bioactive collagen peptides on fingernail health, with a specific focus on women experiencing brittle nails—a common yet often overlooked concern linked to collagen deficiency. By examining the effects of consistent, daily supplementation over an extended period, this study aimed to generate clinically relevant insights into how VERISOL® supports nail strength, growth, and overall quality, while also contributing to the broader understanding of collagen’s role in structural and aesthetic health.

Conducted as an open, single-center clinical trial, the study involved 25 women aged 18-50 who exhibited common symptoms of brittle nails. This trial followed a daily intake of 2.5g of VERISOL® over a duration of 6 months. Additionally, a four-week observation period followed the intervention to assess any sustained effects.

The results of the study shed light on the positive implications of VERISOL® on fingernails. 

• 75% Participants experienced improvements in the quality and growth of their nails, addressing the common issue of brittleness. 
• The trial demonstrated the potential of VERISOL® to contribute to overall nail health, a critical factor in the broader spectrum of collagen-related benefits. 

Clinical Study IV, conducted as an open, single-center trial over a 6-month period, reveals encouraging findings regarding the positive effects of VERISOL® on the quality and growth of fingernails. This study adds to the growing body of evidence supporting the multifaceted benefits of VERISOL® in promoting overall health and well-being.